CRMD CorMedix Forecast, Technical & Fundamental Analysis
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions... Show more
CRMD is expected to report earnings to fall 131.03% to -9 cents per share on November 11
Q3'26
Est.
$-0.09
Q2'26
Beat
by $0.06
Q1'26
Missed
by $0.02
Q4'25
Missed
by $0.69
Q3'25
Beat
by $0.83
The last earnings report on August 13 showed earnings per share of 28 cents, beating the estimate of 23 cents. With 850.35K shares outstanding, the current market capitalization sits at 636.81M.
A.I. Advisor
published General Information
General Information
a developer of medical devices for cardiovascular and kidney diseases
A.I.dvisor indicates that over the last year, CRMD has been loosely correlated with ACRV. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if CRMD jumps, then ACRV could also see price increases.
CRMD's RSI Indicator ascends from oversold territory
The RSI Oscillator for CRMD moved out of oversold territory on July 30, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 31 similar instances when the indicator left oversold territory. In of the 31 cases the stock moved higher. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 62 cases where CRMD's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on August 13, 2026. You may want to consider a long position or call options on CRMD as a result. In of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for CRMD just turned positive on August 13, 2026. Looking at past instances where CRMD's MACD turned positive, the stock continued to rise in of 41 cases over the following month. The odds of a continued upward trend are .
CRMD moved above its 50-day moving average on August 18, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CRMD advanced for three days, in of 282 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The 10-day moving average for CRMD crossed bearishly below the 50-day moving average on July 22, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRMD declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
CRMD broke above its upper Bollinger Band on August 18, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CRMD entered a downward trend on August 07, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.382) is normal, around the industry mean (20.109). P/E Ratio (3.748) is within average values for comparable stocks, (24.032). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.929). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (1.633) is also within normal values, averaging (445.198).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. CRMD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
